Articles tagged "Hepatitis C"

2018 American Transplant Congress
HIV, HBV, and HCV Screening with NAT and Serology in the OPO Setting
N. Theodoropoulos,¹ M. Ison.²
¹UMass Memorial Medical Center, Worcester, MA; ²Northwestern University, Chicago, IL.
Background:In December 2014, the Organ Procurement & Transplantation Network updated policy to mandate screening with nucleic acid tests (NAT) for hepatitis C virus (HCV) in…
2018 American Transplant Congress
Efficacy of Generic Sofosbuvir and Branded Daclatasvir Compared to Sofosbuvir and Ledipasvir Combination in the Treatment of Genotype 4 Hepatitis C Virus
H. Joharji, A. Al-Jedai, D. Alkortas, A. Ajlan, E. Devol, M. Ahmed, F. Aba Al-Khail, H. El-Siesy, M. Al-Sebayel, H. Al-Ashgar, M. Al-Quaiz, W. Alhomodi, A. Aloubal, A. Almohishir.
King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.
Genotype 4 HCV is the most common genotype in Saudi Arabia and the Middle East. Management of genotype 4 HCV has shifted to interferon free…
2018 American Transplant Congress
Mortality and Kidney Transplantation Outcomes among Chronic Dialysis Patients Who Are Seropositive for Hepatitis C Virus
D. Sawinski,¹ F. Kimberly,¹ L. Vincent,¹ S. Justine,¹ B. Colleen,¹ C. Jordana,¹ G. David,¹ L. Jayme,² W. Joe,³ R. Peter.¹
¹Univ of Pennsylvania, Philadelphia, PA; ²Univ of Alabama, Birmingham, AL; ³DaVita, Minneapolis, MN.
Hepatitis C virus (HCV) infection is common among patients receiving chronic dialysis. However, few studies have examined both survival on dialysis as well as transplantation…
2018 American Transplant Congress
Waitlist Outcomes and Access to Liver Transplantation for HIV+ Candidates
A. Shaffer,¹ A. Thomas,¹ A. Massie,¹ S. Gustafson,² J. Snyder,² B. Shelton,³ R. Reed,³ J. Locke,³ D. Segev,^1,2 C. Durand.¹
¹JHU, Baltimore; ²SRTR, Minneapolis; ³UAB, Birmingham.
Liver disease is a leading cause of death for HIV+ individuals, and the number of HIV+ liver transplant recipients is increasing. However, since UNOS does…
2018 American Transplant Congress
Effect of Direct-Acting Hepatitis C Treatment Regimens on Calcineurin Inhibitors in Liver and Kidney Transplant Patients
M. Laub, J. Byrns, M. Harris, C. Berg, S. Sanoff.
Duke University Hospital, Durham, NC.
Background: It has been suggested that treatment with direct-acting antivirals (DAA) for hepatitis C virus (HCV) may decrease calcineurin inhibitor (CNI) concentrations. The purpose of…
2018 American Transplant Congress
Use of Hepatitis-C Treatments after Kidney Transplantation: Impact of the Direct-Acting Antiviral Era
K. Lentine, D. Axelrod,² R. Bloom,³ H. Xiao,¹ D. Segev,⁴ T. Alhamad,⁵ H. Randall,¹ R. Ouseph,¹ V. Dharnidharka,⁵ D. Brennan,⁴ N. Lam,⁶ A. Naik,⁷ G. Hess,⁸ B. Kaiske,⁹ M. Schnitzler.¹
¹Saint Louis U, St. Louis; ²Lahey, Burlington; ³U Penn, Philadelphia; ⁴Johns Hopkins, Baltimore; ⁵Washington U, St. Louis; ⁶U Alberta, Edmonton, Canada; ⁷U Michigan, Ann Arbor; ⁸Hennepin, Minneapolis; ⁹Symphony Health, Conshohocken.
Hepatitis C virus (HCV) infection in kidney transplant (KTx) donors or recipients has correlated with adverse outcomes, partly due to limited treatment options. Development of…
2018 American Transplant Congress
HCV Ab+/NAT- Organ Donors, and the Challenges of 'Eclipse Windows': Analysis of the OPTN/UNOS Ad Hoc Disease Transmission Advisory Committee (DTAC)
C. Wolfe, S. Tlusty, G. Vece, R. Sawyer, R. Bag, G. Berry, J. Bucio, L. Danziger-Isakov, D. Goldberg, C. Ho, D. Florescu, D. Klassen, R. La Hoz, K. Lilly, A. Mehta, M. Malinis, M. Nalesnik, N. Theodoropoulos, P. Wood, M. Michaels.
DTAC, United Network for Organ Sharing, Richmond, VA.
Introduction: In 2017, CDC reported new hepatitis C (HCV) cases had tripled over 5 years, mainly due to intravenous drug use (IVDU). As the proportion…
2018 American Transplant Congress
Outcomes of Antiviral Treatment (AVT) in Hepatitis C Virus (HCV) Liver Transplant (LT) Patients off Immunosuppression (IS) in Direct Acting Antivirals (DAA) Era
E. Agudelo,^1,2 I. Campos-Varela,³ N. Terrault.^1,2
¹Medicine, University of California San Francisco, San Francisco, CA; ²Surgery, University of California San Francisco, San Francisco, CA; ³Internal Medicine, Hospital of Santiago de Compostela, Santiago de Compostela, Spain.
Background: Clearance of HCV under AVT, including DAAs, has been associated with higher risk of rejection, possibly due to the changing immunological environment within the…
2018 American Transplant Congress
Hidden Risk of Liver Transplantation for Nonalcoholic Steatohepatitis: A Propensity Score Matched Study
S. Nagai,¹ R. Schilke,¹ M. Safwan,¹ M. Rizzari,¹ K. Collins,¹ A. Yoshida,¹ M. Abouljoud,¹ D. Moonka.²
¹Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI; ²Gastroenterology, Henry Ford Hospital, Detroit, MI.
Aim: There is a recent shift in the number of liver transplants (LT) performed in patients with hepatitis C (HCV) to those with non-alcoholic steatohepatitis…
2018 American Transplant Congress
Antiviral Therapy for Donor-Derived Hepatitis C Virus Infection after Solid Organ Transplantation
A. Kwong,¹ A. Wall,² M. Melcher,² U. Wang,³ A. Ahmed,¹ K. Khush,³ A. Subramanian,³ J. Tan,³ P. Kwo.¹
¹Gastroenterology and Hepatology, Stanford University, Palo Alto, CA; ²Surgery, Stanford University, Palo Alto, CA; ³Stanford University, Palo Alto, CA.
Background: In the context of organ shortage, the opioid epidemic, and the advent of effective direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV), more…